

News Release

Biofrontera stabilizes shareholder structure

- **Block trade completed off-market**
- **Biofrontera enters essential growth phase with long-term investors**

Leverkusen, 08 April 2015 – Biofrontera AG (AIM/FSE: B8F), the biopharmaceutical company focusing on skin cancer, has stabilized its shareholder structure through an off market block trade of shares. Following intensive selling over the stock markets, the one million remaining shares owned by Dr. Carsten Maschmeyer, through his investment funds, were acquired by existing institutional investors in Biofrontera.

“Biofrontera is in an important growth phase. Developments in 2015 will be core to our future success, in particular with the preparations for the market entry of Ameluz in the USA. In addition, we will progress the indication expansion for basal cell carcinoma in Europe as quickly as possible. In this phase we are delighted by the confidence of investors taking up a block of shares on short notice, signalling their support for the Company’s strategy.” said Biofrontera’s CEO, Prof. Hermann Lübbert.

The shareholder structure of Biofrontera AG is published and regularly updated on Biofrontera’s homepage within the relevant reports.

Ends

News Release

Enquiries, please contact:

Biofrontera AG	+49 (0) 214 87 63 2 0
Prof. Hermann Lübbert, Chief Executive Officer	press@biofrontera.com
Thomas Schaffer, Chief Financial Officer	www.biofrontera.com
IR Germany: Brainwell Asset Solutions	+49 (0) 152 08931514
Jürgen Benker	
Nomad and Broker: Shore Capital	+44(0) 20 7408 4090
Bidhi Bhoma / Toby Gibbs	
IR UK: Seton Services	+44(0) 20 7603 6797
Toni Vallen	
Financial PR: Gable Communications	+44(0) 20 7193 7463
John Bick	+44 (0)7872 061007

Background:

The **Biofrontera Group** (FSE/AIM: B8F, ISIN DE0006046113) is a biopharmaceutical company specialising in the development, sale and distribution of drugs and medical cosmetics for the care and treatment of skin diseases. Biofrontera's most important product is **Ameluz®**, a prescription drug which is approved in Europe for the treatment of mild and moderate actinic keratosis (superficial skin cancer) with photodynamic therapy (light therapy). Biofrontera is the first German pharmaceutical start-up company to obtain centralised approval for a drug it has developed itself. The company also plans for Ameluz® to be approved for basal cell carcinoma and is currently preparing for approval in other countries, especially in the largest pharmaceutical market in the world, the United States.

The company also markets the Belixos® dermatological range of cosmetics. Belixos® products contain combinations of active substances extracted from plants, relieve itching and redness and are used for the regenerative care of chronic skin conditions such as atopic dermatitis or psoriasis. At the moment, Belixos® cream, gel and scalp tonic are available through Amazon.

The Biofrontera Group was established in 1997 by Prof. Dr Hermann Lübbert, the Chairman of the company's Management Board, and has its headquarters in Leverkusen, Germany.

www.biofrontera.com

This communication expressly or implicitly contains certain forward-looking statements concerning the business activities of Biofrontera AG. These forward-looking statements reflect the opinion of Biofrontera at the time of this communication and involve certain known and unknown risks. The actual results achieved by Biofrontera may differ significantly from future results or performances which are published in its forward-looking statements. Biofrontera assumes no responsibility to update its forward-looking statements.